Nuvation Bio Reports Third Quarter Revenue of $45 Million, Exceeding Estimates
Nuvation Bio (NUVB) reported third-quarter financial results that featured a significant revenue beat. The company posted revenue of $45 million, representing a 243% increase year-over-year and exceeding analyst expectations by approximately $10.58 million. While the revenue growth was substantial, the company's GAAP earnings per share (EPS) came in at -$0.12, which aligned with market consensus. The results come amid ongoing investor interest regarding the company's oncology pipeline, specifically its progress in non-small cell lung cancer (NSCLC) and glioma treatments.
Topics: biopharma earnings oncology revenue beat
Read the full article at Seeking Alpha
Part of the story Cardinal Health Reports Strong Q1 Fiscal 2027 Results and Raises Annual EPS Guidance (27 articles)